NASDAQ
Liminatus Pharma, Inc. Class A Common Stock (LIMN) has a fcf yield of -68.85% as of Friday, May 29, 2026. This represents a 1416.41% decrease compared to its 12-month average of -4.54%. Free cash flow yield measures free cash flow per share as a percentage of the stock price, indicating cash return potential.
No price data available for this timeframe.